| EA |
Report |
Net bookings (Q1 FY27, quarter ended June 30, 2026) |
BEAT |
pred ~$1.42B vs. cons ~$1.39B |
LOW |
| EA |
Report |
Net revenue (GAAP, Q1 FY27) |
IN-LINE |
pred ~$1.72B vs. cons ~$1.73B |
LOW |
| EA |
Report |
Diluted EPS (GAAP, Q1 FY27) |
BEAT |
pred ~$0.80 vs. cons ~$0.77 |
LOW |
| EA |
Guide |
FY2027 formal net bookings/EPS guidance |
UNKNOWN |
guide ~$0 (withheld, no formal outlook given pending merger) vs. cons ~$8.3B (FY2027 net bookings consensus est.) |
HIGH |
| EA |
Guide |
Quarterly dividend declaration |
UNCHANGED |
guide ~$0.19 vs. cons $0.19 (Q2 FY27 dividend per share) |
HIGH |
| EA |
Guide |
Merger outside date / CFIUS closing timeline commentary |
UNCHANGED |
guide ~9/28/2026 vs. cons 9/28/2026 (merger agreement outside date, pending CFIUS clearance) |
MEDIUM |
| EA |
Return |
Day-1 residual (stock − beta × S&P 500) |
+0.1% |
— |
LOW |
| EA |
Return |
5-day cumulative residual |
+0.3% (STABILIZE) |
EA is trading as a merger-arb instrument pinned ~0.5% below the $210 all-cash deal price, not as a fundamental story. Even a clean beat/miss on net bookings, revenue or EPS has little room to move the stock because upside is capped near $210 and downside is protected by the definitive agreement and $1B reverse break fee; any 'implicit' forward-estimate cuts from a no-guidance, no-call release are largely irrelevant to price since there is no standalone forward multiple being applied. Day-1 reaction should be muted and dominated by tone (constructive vs. cautious regulatory language) rather than KPI magnitude; over the following days the stock should stabilize near current levels, with any incremental drift driven by the EU Foreign Subsidies Regulation decision (due July 30) and CFIUS headline flow rather than earnings-based re-rating, keeping the path a stabilize rather than a genuine follow-through or fade. |
LOW |